Caris Life Sciences – Continued Commitment to Revolutionize Cancer Care
Dr. George W. Sledge, Jr., newly appointed Executive Vice President and Chief Medical Officer of Caris Life Sciences, discusses why he made the move to Caris and the groundbreaking work he’ll be leading
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. George W. Sledge, Jr. joined Caris Life Sciences in October 2022 and serves as Executive Vice President and Chief Medical Officer. In this role, Dr. Sledge has oversight for medical affairs, research, and medical education, including oversight and leadership for the Caris Precision Oncology Alliance, and Caris’ global team of Medical Science Liaisons.
Prior to joining Caris, Dr. Sledge was Professor of Medicine at the Stanford University School of Medicine where he served as a member of the Division of Oncology. He was most recently co-director of the Stanford Cancer Institute’s Cancer Therapeutics Program and served from 2013-2020 as Chief of the Division of Oncology. Trained in Internal Medicine and Medical Oncology, Dr. Sledge has devoted his professional career to understanding the biology and improving the treatment of breast cancer. He is active as both a laboratory and clinical researcher, with more than 390 scientific publications.
Dr. Sledge has held countless esteemed positions including serving as chair of the Eastern Cooperative Oncology Group’s Breast Cancer Committee (2003-2010), a member of the Food and Drug Administration’s Oncology Drug Advisory Committee, a member of the Department of Defense’s Breast Cancer Research Program’s Integration Panel as well as the National Cancer Institute’s Clinical Trials Advisory Board. He is Past President of the American Society of Clinical Oncology, and served as both the Chief Scientific Advisor for the Susan G. Komen Foundation and member of the Triple Negative Breast Cancer Foundation scientific advisory board.
He has received numerous prestigious honors, notably the Breast Cancer Research Foundation’s Jill Rose Award, the Komen Foundation’s Brinker Award for Scientific Distinction, the San Antonio Breast Cancer Symposium’s William L. McGuire Award and the American Society of Clinical Oncology’s Gianni Bonadonna Award.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
